ClinicalTrials.gg
CompletedNCT05249465Updated Nov 4, 2026Results posted

Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention

An interventional study of Core behavioral weight loss intervention and Self-monitoring diet in Obesity, Overweight and Weight Loss, sponsored by Stanford University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Stanford University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 4, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Obesity by Stanford University — 8 open to participants now, 10 under way, none of them phase 3. Obesity · Stanford University.

Enrollment
22nd of 53
176 · median 102
Started
2023
with 4 others
No phase
42 of 61
6 open now
Registered
51st of 61
by date

Among the 61 studies in Obesity by Stanford University, this one is the 22nd largest by enrollment of the 53 interventional ones that give a count, is one of 5 that started in 2023, is one of 42 with no phase, and was the 51st registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

8 of the 61 studies in Obesity by Stanford University are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Obesity by Stanford University, or all of them as a file.
02

Study summary

This optimization trial will examine three tracking (or "self-monitoring") strategies for weight loss -- tracking dietary intake, steps, and/or body weight -- all delivered through digital health tools. The purpose of the study is to evaluate the combination of these strategies that maximizes 6-month weight loss in the context of a standalone digital health intervention for adults with overweight or obesity.

The investigators will recruit 176 total participants to the trial. Recruitment will occur through remote channels. Interested individuals will be directed to an online screening questionnaire; those who are eligible will then be invited to attend an initial remote session with study personnel to ensure interest and eligibility in the study. The weight loss intervention will last 6 months, and all participants will receive a "core" treatment consisting of goal setting, behavioral lessons, action plans, and tailored feedback - all of which will be delivered remotely. Depending on which group participants are assigned to in the study, some individuals will be asked to track their dietary intake, their steps, and/or their body weight via digital tools. All study tasks will occur remotely, thus, participants never need to come in-person for any intervention or assessment tasks.

The investigators will use the Multiphase Optimization Strategy (MOST) framework to identify the most effective combination of self-monitoring strategies. The factorial design will allow the research team to determine the unique and combined impact of each self-monitoring component on weight change. The primary outcome is weight change from baseline to 6 months. The research team will also assess self-monitoring engagement over 6 months and its association with weight change. To complement the main trial, the research team will also randomize half of participants to receive an interactive orientation video, in order to assess its impact on trial retention at 6 months. Overall, the information gathered from this trial will enable the construction of an optimized digital health intervention for weight loss that can be delivered remotely, which, if found to be effective, could have high potential for scalability.

03

Conditions studied

  • Obesity
  • Overweight
  • Weight Loss
  • Health Behavior

Keywords

  • digital health
  • mobile health
  • intervention
  • weight loss
  • behavioral treatment
  • Multiphase Optimization Strategy (MOST)
  • obesity treatment
  • dietary change
  • physical activity
  • self-monitoring
  • factorial design
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adults (ages 18+ years)
  • (BMI) 25.0 to 45.0 kg/m\^2
  • smartphone ownership
  • willingness to install a mobile app on their phone
  • access to a personal email account
  • English language proficiency
  • interest in losing weight through behavioral strategies

Exclusion criteria

Exclusion Criteria:

  • concurrent enrollment in another weight management intervention
  • loss of ≥10 lbs. in the past 6 months
  • current use of a weight loss medication
  • prior or planned bariatric surgery
  • current or planned pregnancy in the trial period
  • currently breastfeeding
  • lives with someone else participating in the study
  • hospitalization for a mental health condition in the past 12 months
  • inability to engage in moderate forms of physical activity akin to brisk walking (assessed by the Physical Activity Readiness Questionnaire)
  • if weight loss is or might be impacted by a condition or medication (e.g., end stage renal disease, cancer, schizophrenia, dementia, , anti-psychotics)
  • if an individual would be better suited for a more intensive or different type of intervention based on a health condition (e.g., individuals with history of an eating disorder or cardiovascular event, uncontrolled hypertension, or uncontrolled diabetes mellitus)
  • investigator discretion for safety reasons
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
176 participants (actual)

Study arms

  • Experimental
    Condition 1

    Core Only

    Behavioral: Core behavioral weight loss intervention

  • Experimental
    Condition 2

    Core + Track Weight

    Behavioral: Core behavioral weight loss intervention · Behavioral: Self-monitoring weight

  • Experimental
    Condition 3

    Core + Track Steps

    Behavioral: Core behavioral weight loss intervention · Behavioral: Self-monitoring steps

  • Experimental
    Condition 4

    Core + Track Diet

    Behavioral: Core behavioral weight loss intervention · Behavioral: Self-monitoring diet

  • Experimental
    Condition 5

    Core + Track Weight + Track Steps

    Behavioral: Core behavioral weight loss intervention · Behavioral: Self-monitoring weight · Behavioral: Self-monitoring steps

  • Experimental
    Condition 6

    Core + Track Weight + Track Diet

    Behavioral: Core behavioral weight loss intervention · Behavioral: Self-monitoring diet · Behavioral: Self-monitoring weight

  • Experimental
    Condition 7

    Core + Track Steps + Track Diet

    Behavioral: Core behavioral weight loss intervention · Behavioral: Self-monitoring diet · Behavioral: Self-monitoring steps

  • Experimental
    Condition 8

    Core + Track Weight + Track Steps + Track Diet

    Behavioral: Core behavioral weight loss intervention · Behavioral: Self-monitoring diet · Behavioral: Self-monitoring weight · Behavioral: Self-monitoring steps

Interventions

  • BehavioralCore behavioral weight loss intervention

    All participants will receive a 6-month "core" behavioral obesity treatment consisting of goal setting, behavioral lessons, action plans, and tailored feedback - all of which will be delivered remotely.

  • BehavioralSelf-monitoring diet

    Participants randomized to receive this component will be instructed to self-monitor their dietary intake daily via the Fitbit mobile app. Participants will receive a daily calorie goal.

  • BehavioralSelf-monitoring weight

    Participants randomized to receive this component will be instructed to self-monitor their body weight daily via a wireless e-scale (e.g., the Fitbit Aria Scale).

  • BehavioralSelf-monitoring steps

    Participants randomized to receive this component will be instructed to self-monitor their step count daily via a wrist-worn Fitbit activity monitor. A daily step goal will be given that will adapt based on progress.

06

What researchers measure

Primary outcomes

  1. Body Weight Change From Baseline to 6 Months

    change in weight from baseline to 6-month followup (in kg); assessed objectively via e-scale

    Time frame: baseline, 6 months

Secondary outcomes

  1. Body Weight From Baseline to 1 Month

    change in weight from baseline to 1-month followup (in kg); assessed objectively via e-scale

    Time frame: baseline, 1 month

  2. Body Weight From Baseline to 3 Months

    change in weight from baseline to 3-month followup (in kg); assessed objectively via e-scale

    Time frame: baseline, 3 month

  3. Clinically Significant Weight Loss

    proportion of participants achieving ≥5% weight loss from baseline

    Time frame: 6 months

  4. BMI Change From Baseline to 6 Months

    change in BMI from baseline to 6-month followup (in kg/m\^2); computed from self-reported height and e-scale weight

    Time frame: baseline, 6 months

  5. Caloric Intake Change From Baseline to 6 Months

    change in caloric intake from baseline to 6-month followup (in kcal); assessed using Automated 24-Hour (ASA-24) Dietary Assessment Tool (2 separate 24hr diet recalls at each time point: 1 week day, 1 weekend day)

    Time frame: baseline, 6 months

  6. Physical Activity Change From Baseline to 6 Months

    change in physical activity from baseline to 6-month followup; assessed using Godin Leisure-Time Exercise Questionnaire (GLTEQ)'s MVPA Score Index. The GLTEQ is a self-report measure that assesses a typical week's frequency of engaging in different types of exercise for at least 15 minutes. Minimum score is 0; there is no maximum score. Higher scores indicate more frequent moderate-to-vigorous physical activity. Scores ≥ 24 indicate "active" while scores \< 24 indicate "insufficiently active."

    Time frame: baseline, 6 months

  7. Engagement in Self-monitoring Dietary Intake

    average percent of days in the 6-month intervention of self-monitoring dietary intake; assessed objectively via digital health tools (mobile app)

    Time frame: 6 months of the intervention

  8. Engagement in Self-monitoring Weight

    average percent of days in the 6-month intervention of self-monitoring weight; assessed objectively via digital health tools (e-scale)

    Time frame: 6 months of the intervention

  9. Engagement in Self-monitoring Steps

    average percent of days in the 6-month intervention of self-monitoring steps; assessed objectively via digital health tools (activity monitor)

    Time frame: 6 months of the intervention

07

Results

Posted Nov 4, 2026

Participant flow

Participants were enrolled in the Spark trial between September 22, 2023 and November 18, 2024. The trial was fully remote, with recruitment of adults across the United States.

Participant flow — Overall Study
MilestoneCondition 1Condition 2Condition 3Condition 4Condition 5Condition 6Condition 7Condition 8
Started2222222222222222
Completed2120211919192118
Not completed12133314

Outcome measures

PrimaryBody Weight Change From Baseline to 6 Months

change in weight from baseline to 6-month followup (in kg); assessed objectively via e-scale

Time frame:
baseline, 6 months
Reported as:
Mean · kg
Body Weight Change From Baseline to 6 Months
kgSelf-Monitoring Diet: YesSelf-Monitoring Diet: NoSelf-Monitoring Steps: YesSelf-Monitoring Steps: NoSelf-Monitoring Weight: YesSelf-Monitoring Weight: No
Body Weight Change From Baseline to 6 Months-4.5 ± 5.9-1.9 ± 5.0-2.9 ± 6.0-3.4 ± 5.2-3.6 ± 5.5-2.8 ± 5.7
Statistical analysis
  • Self-Monitoring Diet: Yes vs Self-Monitoring Diet: No · Mean difference (net): -2.36 · 95% CI -3.98 to -0.73Negative numbers for the mean difference estimate represent greater weight loss from baseline when the component was present (coded as +1) than when the component was absent (coded as -1).
  • Self-Monitoring Steps: Yes vs Self-Monitoring Steps: No · Mean difference (net): 0.60 · 95% CI -1.03 to 2.22Negative numbers for the mean difference estimate represent greater weight loss from baseline when the component was present (coded as +1) than when the component was absent (coded as -1).
  • Self-Monitoring Weight: Yes vs Self-Monitoring Weight: No · Mean difference (net): -0.92 · 95% CI -2.55 to 0.71Negative numbers for the mean difference estimate represent greater weight loss from baseline when the component was present (coded as +1) than when the component was absent (coded as -1).
SecondaryBody Weight From Baseline to 1 Month

change in weight from baseline to 1-month followup (in kg); assessed objectively via e-scale

Time frame:
baseline, 1 month
Reported as:
Mean · kg
Body Weight From Baseline to 1 Month
kgSelf-Monitoring Diet: YesSelf-Monitoring Diet: NoSelf-Monitoring Steps: YesSelf-Monitoring Steps: NoSelf-Monitoring Weight: YesSelf-Monitoring Weight: No
Body Weight From Baseline to 1 Month-1.7 ± 1.9-0.6 ± 2.4-1.2 ± 2.1-1.1 ± 2.3-1.6 ± 2.3-0.7 ± 2.0
Statistical analysis
  • Self-Monitoring Diet: Yes vs Self-Monitoring Diet: No · Mean difference (net): -0.98 · 95% CI -1.61 to -0.36Negative values for weight change reflect weight loss. Thus, negative values for the mean difference estimate represent greater weight loss from baseline when the component was present (coded as +1) than when the component was absent (coded as -1).
  • Self-Monitoring Steps: Yes vs Self-Monitoring Steps: No · Mean difference (net): -0.13 · 95% CI -0.75 to 0.50Negative values for weight change reflect weight loss. Thus, negative values for the mean difference estimate represent greater weight loss from baseline when the component was present (coded as +1) than when the component was absent (coded as -1).
  • Self-Monitoring Weight: Yes vs Self-Monitoring Weight: No · Mean difference (net): -0.87 · 95% CI -1.50 to -0.24Negative values for weight change reflect weight loss. Thus, negative values for the mean difference estimate represent greater weight loss from baseline when the component was present (coded as +1) than when the component was absent (coded as -1).
SecondaryBody Weight From Baseline to 3 Months

change in weight from baseline to 3-month followup (in kg); assessed objectively via e-scale

Time frame:
baseline, 3 month
Reported as:
Mean · kg
Body Weight From Baseline to 3 Months
kgSelf-Monitoring Diet: YesSelf-Monitoring Diet: NoSelf-Monitoring Steps: YesSelf-Monitoring Steps: NoSelf-Monitoring Weight: YesSelf-Monitoring Weight: No
Body Weight From Baseline to 3 Months-3.0 ± 4.0-1.5 ± 3.6-2.3 ± 4.0-2.2 ± 3.8-2.8 ± 3.7-1.7 ± 4.0
Statistical analysis
  • Self-Monitoring Diet: Yes vs Self-Monitoring Diet: No · Mean difference (net): -1.45 · 95% CI -2.58 to -0.32Negative values for weight change reflect weight loss. Thus, negative values for the mean difference estimate represent greater weight loss from baseline when the component was present (coded as +1) than when the component was absent (coded as -1).
  • Self-Monitoring Steps: Yes vs Self-Monitoring Steps: No · Mean difference (net): -0.10 · 95% CI -1.23 to 1.03Negative values for weight change reflect weight loss. Thus, negative values for the mean difference estimate represent greater weight loss from baseline when the component was present (coded as +1) than when the component was absent (coded as -1).
  • Self-Monitoring Weight: Yes vs Self-Monitoring Weight: No · Mean difference (net): -1.31 · 95% CI -2.43 to -0.18Negative values for weight change reflect weight loss. Thus, negative values for the mean difference estimate represent greater weight loss from baseline when the component was present (coded as +1) than when the component was absent (coded as -1).
SecondaryClinically Significant Weight Loss

proportion of participants achieving ≥5% weight loss from baseline

Time frame:
6 months
Reported as:
Count of participants · Participants
Clinically Significant Weight Loss
ParticipantsSelf-Monitoring Diet: YesSelf-Monitoring Diet: NoSelf-Monitoring Steps: YesSelf-Monitoring Steps: NoSelf-Monitoring Weight: YesSelf-Monitoring Weight: No
Clinically Significant Weight Loss432533353731
Statistical analysis
  • Self-Monitoring Diet: Yes vs Self-Monitoring Diet: No · Risk ratio (rr): 1.72 · 95% CI 1.15 to 2.56A risk ratio \>1 indicates that participants were more likely to achieve clinically significant weight loss of ≥5% at 6 months when the component was present (coded as +1) vs. when it was absent (coded as -1).
  • Self-Monitoring Steps: Yes vs Self-Monitoring Steps: No · Risk ratio (rr): 0.97 · 95% CI 0.65 to 1.44A risk ratio \>1 indicates that participants were more likely to achieve clinically significant weight loss of ≥5% at 6 months when the component was present (coded as +1) vs. when it was absent (coded as -1).
  • Self-Monitoring Weight: Yes vs Self-Monitoring Weight: No · Risk ratio (rr): 1.19 · 95% CI 0.80 to 1.78
SecondaryBMI Change From Baseline to 6 Months

change in BMI from baseline to 6-month followup (in kg/m\^2); computed from self-reported height and e-scale weight

Time frame:
baseline, 6 months
Reported as:
Mean · kg/m^2
BMI Change From Baseline to 6 Months
kg/m^2Self-Monitoring Diet: YesSelf-Monitoring Diet: NoSelf-Monitoring Steps: YesSelf-Monitoring Steps: NoSelf-Monitoring Weight: YesSelf-Monitoring Weight: No
BMI Change From Baseline to 6 Months-1.6 ± 2.0-0.6 ± 1.7-1.0 ± 2.0-1.2 ± 1.8-1.3 ± 1.9-0.9 ± 2.0
Statistical analysis
  • Self-Monitoring Diet: Yes vs Self-Monitoring Diet: No · Mean difference (net): -0.87 · 95% CI -1.43 to -0.31Negative values for BMI change reflect a decrease in BMI. Thus, negative values for the mean difference estimate represent greater declines in BMI from baseline when the component was present (coded as +1) than when it absent (coded as -1).
  • Self-Monitoring Steps: Yes vs Self-Monitoring Steps: No · Mean difference (net): 0.19 · 95% CI -0.37 to 0.75Negative values for BMI change reflect a decrease in BMI. Thus, negative values for the mean difference estimate represent greater declines in BMI from baseline when the component was present (coded as +1) than when it absent (coded as -1).
  • Self-Monitoring Weight: Yes vs Self-Monitoring Weight: No · Mean difference (net): -0.37 · 95% CI -0.94 to 0.19Negative values for BMI change reflect a decrease in BMI. Thus, negative values for the mean difference estimate represent greater declines in BMI from baseline when the component was present (coded as +1) than when it absent (coded as -1).
SecondaryCaloric Intake Change From Baseline to 6 Months

change in caloric intake from baseline to 6-month followup (in kcal); assessed using Automated 24-Hour (ASA-24) Dietary Assessment Tool (2 separate 24hr diet recalls at each time point: 1 week day, 1 weekend day)

Time frame:
baseline, 6 months
Reported as:
Mean · kcal
Caloric Intake Change From Baseline to 6 Months
kcalSelf-Monitoring Diet: YesSelf-Monitoring Diet: NoSelf-Monitoring Steps: YesSelf-Monitoring Steps: NoSelf-Monitoring Weight: YesSelf-Monitoring Weight: No
Caloric Intake Change From Baseline to 6 Months-461.8 ± 771.3-274.2 ± 557.4-382.4 ± 658.1-349.2 ± 692.9-426.3 ± 732.0-304.4 ± 609.8
Statistical analysis
  • Self-Monitoring Diet: Yes vs Self-Monitoring Diet: No · Mean difference (net): -110.96 · 95% CI -288.65 to 66.73Negative values reflect a decrease in caloric intake from baseline. Thus, negative values for the mean difference estimate represent greater declines in caloric intake when the component was present (coded as +1) than when it absent (coded as -1).
  • Self-Monitoring Steps: Yes vs Self-Monitoring Steps: No · Mean difference (net): 54.32 · 95% CI -123.33 to 231.97Negative values reflect a decrease in caloric intake from baseline. Thus, negative values for the mean difference estimate represent greater declines in caloric intake when the component was present (coded as +1) than when it absent (coded as -1).
  • Self-Monitoring Weight: Yes vs Self-Monitoring Weight: No · Mean difference (net): -117.81 · 95% CI -295.54 to 59.92Negative values reflect a decrease in caloric intake from baseline. Thus, negative values for the mean difference estimate represent greater declines in caloric intake when the component was present (coded as +1) than when it absent (coded as -1).
SecondaryPhysical Activity Change From Baseline to 6 Months

change in physical activity from baseline to 6-month followup; assessed using Godin Leisure-Time Exercise Questionnaire (GLTEQ)'s MVPA Score Index. The GLTEQ is a self-report measure that assesses a typical week's frequency of engaging in different types of exercise for at least 15 minutes. Minimum score is 0; there is no maximum score. Higher scores indicate more frequent moderate-to-vigorous physical activity. Scores ≥ 24 indicate "active" while scores \< 24 indicate "insufficiently active."

Time frame:
baseline, 6 months
Reported as:
Mean · units on a scale
Physical Activity Change From Baseline to 6 Months
units on a scaleSelf-Monitoring Diet: YesSelf-Monitoring Diet: NoSelf-Monitoring Steps: YesSelf-Monitoring Steps: NoSelf-Monitoring Weight: YesSelf-Monitoring Weight: No
Physical Activity Change From Baseline to 6 Months4.8 ± 22.32.3 ± 16.26.7 ± 18.80.5 ± 19.53.8 ± 18.23.3 ± 20.5
Statistical analysis
  • Self-Monitoring Diet: Yes vs Self-Monitoring Diet: No · Mean difference (net): -2.46 · 95% CI -9.02 to 4.09Positive values reflect an increase in physical activity from baseline. Thus, positive values for the mean difference estimate represent greater physical activity when the component was present (coded as +1) than when it absent (coded as -1).
  • Self-Monitoring Steps: Yes vs Self-Monitoring Steps: No · Mean difference (net): 4.42 · 95% CI -2.14 to 10.97Positive values reflect an increase in physical activity from baseline. Thus, positive values for the mean difference estimate represent greater physical activity when the component was present (coded as +1) than when it absent (coded as -1).
  • Self-Monitoring Weight: Yes vs Self-Monitoring Weight: No · Mean difference (net): 1.46 · 95% CI -5.09 to 8.01Positive values reflect an increase in physical activity from baseline. Thus, positive values for the mean difference estimate represent greater physical activity when the component was present (coded as +1) than when it absent (coded as -1).
SecondaryEngagement in Self-monitoring Dietary Intake

average percent of days in the 6-month intervention of self-monitoring dietary intake; assessed objectively via digital health tools (mobile app)

Time frame:
6 months of the intervention
Reported as:
Median · % of days in the 6-month intervention
Engagement in Self-monitoring Dietary Intake
% of days in the 6-month interventionSelf-Monitoring Diet: Yes
Engagement in Self-monitoring Dietary Intake48.1 (14.7 to 82.6)
SecondaryEngagement in Self-monitoring Weight

average percent of days in the 6-month intervention of self-monitoring weight; assessed objectively via digital health tools (e-scale)

Time frame:
6 months of the intervention
Reported as:
Median · % of days in the 6-month intervention
Engagement in Self-monitoring Weight
% of days in the 6-month interventionSelf-Monitoring Weight: Yes
Engagement in Self-monitoring Weight76.4 (33.0 to 94.1)
SecondaryEngagement in Self-monitoring Steps

average percent of days in the 6-month intervention of self-monitoring steps; assessed objectively via digital health tools (activity monitor)

Time frame:
6 months of the intervention
Reported as:
Median · % of days in the 6-month intervention
Engagement in Self-monitoring Steps
% of days in the 6-month interventionSelf-Monitoring Steps: Yes
Engagement in Self-monitoring Steps95.6 (65.1 to 99.0)

Adverse events

Collected over From randomization until end of the 6-month intervention. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Condition 10/22 (0%)0/22 (0%)0/22 (0%)
Condition 20/22 (0%)1/22 (4.5%)0/22 (0%)
Condition 30/22 (0%)0/22 (0%)0/22 (0%)
Condition 40/22 (0%)0/22 (0%)0/22 (0%)
Condition 50/22 (0%)0/22 (0%)3/22 (13.6%)
Condition 60/22 (0%)0/22 (0%)0/22 (0%)
Condition 70/22 (0%)0/22 (0%)1/22 (4.5%)
Condition 80/22 (0%)1/22 (4.5%)2/22 (9.1%)
Most frequent serious events
Most frequent serious events
EventCondition 1Condition 2Condition 3Condition 4Condition 5Condition 6Condition 7Condition 8
HyperthyroidismEndocrine disorders0/221/220/220/220/220/220/220/22
Lung cancer with hospitalizationNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/220/220/220/220/220/220/221/22
Most frequent other events
Most frequent other events
EventCondition 1Condition 2Condition 3Condition 4Condition 5Condition 6Condition 7Condition 8
Covid-19Infections and infestations0/220/220/220/221/220/221/220/22
Disordered eatingPsychiatric disorders0/220/220/220/221/220/220/220/22
Unspecified, unrelated health issueGeneral disorders0/220/220/220/221/220/220/220/22
Strep throatRespiratory, thoracic and mediastinal disorders0/220/220/220/220/220/221/220/22
Skin irritation from activity trackerSkin and subcutaneous tissue disorders0/220/220/220/220/220/220/221/22
Unspecified illness due to severe stress from personal matterPsychiatric disorders0/220/220/220/220/220/220/221/22

Baseline characteristics

Age, Continuous
Age, Continuous(years)Condition 1Condition 2Condition 3Condition 4Condition 5Condition 6Condition 7Condition 8Total
Mean39.7 ± 20.048.9 ± 19.742.6 ± 19.543.3 ± 19.346.0 ± 19.144.6 ± 18.946.8 ± 18.746.1 ± 18.544.7 ± 15.3
Sex: Female, Male
Sex: Female, Male(Participants)Condition 1Condition 2Condition 3Condition 4Condition 5Condition 6Condition 7Condition 8Total
Female1616161616161616128
Male6666666648
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Condition 1Condition 2Condition 3Condition 4Condition 5Condition 6Condition 7Condition 8Total
American Indian or Alaska Native000010113
Asian6131314221
Native Hawaiian or Other Pacific Islander000000000
Black or African American3447252330
White1216131313151315110
More than one race1121312112
Unknown or Not Reported000000000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Condition 1Condition 2Condition 3Condition 4Condition 5Condition 6Condition 7Condition 8Total
Hispanic or Latino4541234427
Not Hispanic or Latino1817182120191818149
Unknown or Not Reported000000000
Weight
Weight(kg)Condition 1Condition 2Condition 3Condition 4Condition 5Condition 6Condition 7Condition 8Total
Mean88.2 ± 32.585.5 ± 32.290.7 ± 31.989.4 ± 31.791.5 ± 31.496.9 ± 31.195.1 ± 30.886.6 ± 30.690.5 ± 17.1
08

Study locations

1 site
  • Stanford University School of Medicine
    Stanford, California 94305, United States
09

References and documents

Publications

  • Patel ML, King AC, Rosas LG, Bennett GG, Collins LM, Gallis JA, Zeitlin AB, Talreja PS, Crosthwaite PC, Collins KA, Lim AW, Kim TS. Optimizing Self-Monitoring in a Digital Weight Loss Intervention (Spark): Protocol for a Factorial Randomized Trial. JMIR Res Protoc. 2025 Sep 23;14:e75629. doi: 10.2196/75629. PubMed 40986860 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Once the study data have undergone final data cleaning, analysis, and planned publications, the investigators will make the final data collected as part of the proposed research available in electronic form to researchers who request them. Researchers will be asked to submit a data request in writing to the Principal Investigator so that the requested data can be made available while protecting the confidentiality of study participants and ensuring that the proposed research questions do not overlap with planned publication development by the project research team or other groups. The requested dataset will be free of identifiers that would permit linkages to individual research participants. The requestor must agree to maintain the privacy and confidentiality of the data and must indicate how they plan to store the data to demonstrate compliance with secure computing. All publications that emerge from this award will be publicly available via PubMed Central.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Jun 2025, 20 months.

Results were first posted in Nov 2026, 1 year 4 months after primary completion.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 20 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2022
First posted
Feb 21, 2022
StartActual
Sep 22, 2023
Primary completionActual
Jun 15, 2025
CompletionActual
Jun 23, 2025
Results first posted
Nov 4, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 4, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedBody weight change from baselineWeight Change From Baseline to 6 monthsMonthsTime frame: baseline, 6 months
Nov 4, 2026
Documents
Secondary outcomes
9 edited
What changed in the outcomes
  • EditedBody weight from baselineWeight From Baseline to 1 monthMonthTime frame: baseline, 1 month
  • EditedBody weight from baselineWeight From Baseline to 3 monthsMonthsTime frame: baseline, 3 month
  • EditedClinically significant weight lossSignificant Weight LossTime frame: 6 months
  • EditedBMI change from baselineChange From Baseline to 6 monthsMonthsTime frame: baseline, 6 months
  • EditedCaloric intake change from baselineIntake Change From Baseline to 6 monthsMonthsTime frame: baseline, 6 months
  • EditedPhysical activity change from baselineActivity Change From Baseline to 6 monthsMonthsTime frame: baseline, 6 months
  • EditedEngagement in selfSelf-monitoring dietary intakeDietary IntakeTime frame: 6 months of the intervention
  • EditedEngagement in selfSelf-monitoring weightWeightTime frame: 6 months of the intervention
  • EditedEngagement in selfSelf-monitoring stepsStepsTime frame: 6 months of the intervention
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedBody weight change from baselineWeight Change From Baseline to 6 monthsMonthsTime frame: baseline, 6 months
    Secondary outcomes 9 edited
    What changed in the outcomes
    • EditedBody weight from baselineWeight From Baseline to 1 monthMonthTime frame: baseline, 1 month
    • EditedBody weight from baselineWeight From Baseline to 3 monthsMonthsTime frame: baseline, 3 month
    • EditedClinically significant weight lossSignificant Weight LossTime frame: 6 months
    • EditedBMI change from baselineChange From Baseline to 6 monthsMonthsTime frame: baseline, 6 months
    • EditedCaloric intake change from baselineIntake Change From Baseline to 6 monthsMonthsTime frame: baseline, 6 months
    • EditedPhysical activity change from baselineActivity Change From Baseline to 6 monthsMonthsTime frame: baseline, 6 months
    • EditedEngagement in selfSelf-monitoring dietary intakeDietary IntakeTime frame: 6 months of the intervention
    • EditedEngagement in selfSelf-monitoring weightWeightTime frame: 6 months of the intervention
    • EditedEngagement in selfSelf-monitoring stepsStepsTime frame: 6 months of the intervention
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05249465
Responsible party
Michele Patel (Instructor, Stanford University) — Principal investigator
First posted
Feb 21, 2022
Start date
Sep 22, 2023
Primary completion
Jun 15, 2025
Completion
Jun 23, 2025
Results posted
Nov 4, 2026
Last update
Nov 4, 2026

Study contacts

Michele L Patel, PhD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion